![Jan Pinkas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Pinkas
No open positions remaining
Net worth: 400 302 $ as of 2026-06-29
Profile
Jan Pinkas is Chief Scientific Officer at Crescent Biopharma, Inc. since 2025.
Former roles include Chief Scientific Officer at Pyxis Oncology, Inc. from 2022 to 2025, VP-Translational Research & Development at ImmunoGen, Inc., and Senior Vice President-Translation Services at Magenta Therapeutics, Inc. Education includes undergraduate studies at The Johns Hopkins University and a doctorate from the University of Massachusetts.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.08% | 2026-06-21 | 22,239 ( 0.08% ) | 400 302 $ | 2026-06-29 |
Jan Pinkas active positions
| Companies | Position | Start |
|---|
Former positions of Jan Pinkas
| Companies | Position | End |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 2025-02-28 |
| IMMUNOGEN, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Training of Jan Pinkas
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
2
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Massachusetts
 University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
- Stock Market
- Insiders
- Jan Pinkas
